Aktar

@LearningEleven Congratulations 👏👏👏🎉

My son has cleared CFA Level III, results were announced today. Truly a very satisfying day! Perhaps it’s a different generation, but at 21, my exposure was largely limited to academics.

@itsTarH Thank you Sir

@futurefor2030 We are having temporary deliverability related issues for gmail accounts. We have enabled a Sign in with Google option at the login page so you can sign in directly via your google account. The OTP functionality will also be fixed in the next few hours.

Latest #TheWrap🌯is now available to read ⤵️ Discover special situations, sector rotation, insider trades, bulk and block deals, new listings, order wins, earnings review & more thewrap.in/blog/thewrap145 Your one stop place for everything important in Indian Stock Market

@ishmohit1 But sir that is too very high inflation country

Just finishing my vacation in Indonesia. Beautiful country with good people and most importantly one of the places where Indian rupees purchasing power feels good. Quite affordable 1 lakh Indonesian rupees= 550 INR :)

@Prakashplutus its out of ur level! lol

IRAN is attacking UAE more than Israel . IRAN can’t hit USA , Hence they are hitting UAE to keep @realDonaldTrump under check . But hitting your neighbour regularly is not Cool , that too a Muslim country .

@Prakashplutus @realDonaldTrump lol

@Prakashplutus lol

IRAN is doing almost the same thing with UAE , what USA is doing with Iran .

@ADX_Learner I already deployed cash

#niftyfifty The level of 21700-22000 I am waiting to deploy my cash. What level you are waiting for..🤔 Pleaee share..🤗 🙏🙏

@ADX_Learner Working fine

#Beta Drugs Ltd Monthly Chart. Will it change its direction from here ? Keep👀

@JoshiEien Sir it will give benefit to some downstream companies for lower input cost ! what is your view on this

Negative for Indian chemical players. Positive for EU & China! To ease sourcing of chemicals, GoI is planning to exempt whole of custom duty ( most of the products 7.5% + 10% Surcharge = 8.25%) temporarily from 02 Apr’26 to 30 Jun’26 on below chemicals.

@thechartist26 He he

So, in a tougher market like this, I don't think my vacation can help the tourism index form a base.

@LearningEleven Sir any view on Neuland Lab !

Timepass talk on Sunday As we step into FY27, the plan for this week and next is to revisit and present companies with strong FY27 triggers. Most of these have been discussed earlier in previous editions of Timepass Talk on Sunday, so in that sense, this is a bit of a ‘blast from the past’. Here we go: 1. Accent Microcell If the past 4–5 months have been a brutal phase for small and micro caps, Accent Microcell stands out as a relative outperformer. The stock has held firm, not breaching the ₹320 mark even during peak volatility. With fresh capacities expected to come on stream shortly, the company could be nearing the start of a meaningful earnings cycle. Whether it can meaningfully chip away at Sigachi’s market share, and potentially emerge as a multibagger by FY27, remains an open question. That said, while parts of the market are highly optimistic, others continue to flag key concerns, particularly around execution. Why the concern? The delay in commissioning new capacity has become a never-ending story, first April ’25, then October ’25, then December ’25, and now pushed to April ’26. No one really knows what’s causing the slippage, yet the stock hasn’t corrected much. CY2026 could well be the defining year, either where narrative finally translates into execution, or the market begins to lose patience with the story. 2. Concord Biotech This fermentation-based (sunrise space) biopharma company is an interesting study. While FY26 was largely disappointing year from earnings perspective, valuations are finally started to cool-off. The had reported multiple issues in FY26: i) EU supply interruption due to CDSCO written confirmation delay - This did not allow Concord to sell in the European market for a couple of months, however, this is resolved in Q3 but management cautioned that ramp-up will be gradual. ii) Middle East tender deferral - It is still a concern and with the ongoing Iran war situation, might take much longer for this to be resolved iii) Temporary US procurement slowdown amid tariff uncertainty - This has hurt them bad for couple of quarters (leading to de-operating leverage) but situation seems to be getter better. Should help in FY27. Additionally, depreciation and start-up costs from the newly commissioned injectables facility are already flowing through the P&L, suppressing PAT ahead of revenue scale-up. However, FY27 should be much better than FY26. P/S has cooled off from 18 in June 2025 to 9 in March 2026, is that a fair valuation or not is an individual investor choice! 3. India’s CDMO Inflection Point - FY27 Clearly, India’s CDMO opportunity is still much smaller than China’s, but relative to where we were a few years ago, the ecosystem has evolved meaningfully. FY27–FY28 could well turn out to be the scale years for the sector. Acutaas: Guided for ~₹1,000 crore CDMO revenue by FY28, with four products validated in FY26 expected to start contributing to the topline from FY27, providing clear visibility into the next phase of growth. In parallel, the company has taken a strategic step into semiconductor chemicals, specifically raw materials for photoresists, through its South Korea acquisition, adding a new high-growth vertical to the business. That said, the stock has seen a sharp run-up recently and may not offer the most attractive entry point at current valuations. Navin Fluorine: CDMO revenues of ₹360 crore in 9MFY26, with a target of ₹850–880 crore (~$100 million) by FY27. The company has a pipeline of 10–15 molecules. Beyond CDMO, multiple capacities in other verticals are expected to go live in FY27 offering strong earnings uptick! Sai Life Sciences: Manufacturing capacity to expand from ~700 KL in FY26 to 925 KL by Q1FY27 and 1,150 KL by Q4FY27 (≈65% increase). Added 7 molecules in FY26 (3 commercial, 4 in Phase III). Sai will be the primary supplier in two of these molecules . They are expected to sustain the margins in the range of 28% to 30%. Divi’s Laboratories: Three large dedicated projects under execution, with commercial volumes expected from H2CY27. Over 18 MT peptide capacity, including Tirzepatide and potentially Orforglipron post regulatory approvals. GLP molecules are expected to add significant growth! Laurus Labs: Barring a few logistical disruptions stemming from the Iran conflict, the company is expected to deliver a strong Q4 and maintain healthy growth in FY27 over FY26. Valuations may not appear cheap, but as the saying goes, value ultimately lies in the eye of the beholder. 4. GRSE - the revenue cycle is getting bigger I had written earlier about how earnings cycles in shipbuilding are inherently volatile, and why accumulating at lower valuations is key to generating outsized returns. I had already discussed about how FY22-26 cycle played out, so, let’s focus on what lies ahead: FY27: Likely peak revenue year (driven by P-17 Alpha execution) FY28: A transition/bridge year between two shipbuilding cycles FY29–FY35: Next major build cycle If P-17 Bravo and other orders materialize, we could be looking at a repeat of the FY22–FY26 kind of growth (and returns) when the stock had given 6-7x returns. The investing takeaway: GRSE is NOT a linear growth story. It is a cycle-driven compounding story. Buy during weak phases → hold through the build cycle → earnings catch up later. GRSE was trading at 80+ P/E 9 months ago! Its five-year median P/E stands at ~31, while the current P/E is around 34. This isn’t a buy or sell call, but for those looking to play the shipping theme, these are the kinds of corrections worth watching. 5. Shilpa Medicare - FY27 may be the real inflection year Back in Q4 FY24, the market expected FY25 to be the breakthrough year for Shilpa Medicare. The stock priced that in, it nearly doubled between Feb/Mar 2024 and Nov 2024. But fundamentals didn’t catch up immediately. H1 FY25 PAT was only ~₹32 Cr, far below expectations, and the stock corrected ~33% in just three months. So why revisit it now? Because it increasingly looks like the “breakthrough year” wasn’t wrong, just delayed. Instead of FY25, it appears to be shifting to FY26. FY25 PAT: ~₹78 Cr and 9M FY26 PAT: ~₹136 Cr already In the Q3 FY26 investor deck, the MD even stated: “...We are confident in a significantly better FY27...” What’s driving that confidence? API & CDMO • NCE pipeline: Three active U.S. NCE programs — one already commercialized, the second in Phase 3, and the third (with Unicycive Therapeutics) getting a dedicated commercial block by Q4 FY26. • Oncology APIs: Added 10 new blockbuster oncology products to the development grid; 3 validated this quarter. • Peptides: Developing semaglutide (oral and injectable). Large-scale peptide manufacturing capex underway; targeted completion in H2 FY27. Formulations (FDF): Fastest-growing segment • Nor-UDCA: Launched in Q3 with strong physician response and a firm order book for Q4. Europe and U.S. expansion planned. • Transdermal patch: EMA approval received for rotigotine; U.S. filing expected in Q4 FY26 with a potential FY27 launch. • Complex injectables: Long-acting ondansetron injection Phase 3 completed; India launch expected in H1 FY27. Biologics & Biosimilars • Aflibercept biosimilar (ophthalmology): Phase 3 on track for H1 FY27 submission. • Albumin: Global clinical trial protocol approved; Europe filing targeted in Q4 FY26. This is a multi-billion-dollar global market opportunity. This edition wraps up the financial year. See you in the next one!

@varinder_bansal lag raha hai ghar main LPG khatam ho gaya hai aur dubai main holiday manane giya hai office tour ke naam pe 😜😜😜😜

I don't tweet for publicity or money. Never been paid to post anything. But some people use uncertainty to skip facts, spread lies, and create panic. The world is anxious enough. Don't add to it. PS: Largest crowd I've seen in Downtown Dubai this whole week — and it was today.

@LearningEleven thanks Sir for wonderful Sunday Morning time pass reading ! love u Sir 🩷

@EquityValueIn Superb work 👍👍

Apollo pipes is up >50% in since initiation , you all know I had been doing the work on pipes since 4 quarters that in my quarterly rate of change pessimism tracker talking about sector and understanding where we were , tracked 4 quarters , pulled the trigger on peak pessimism , and market has rewarded that too in these tough times with luck also favoring the process ! Process driven research and courage driven execution discipline is a combo that has rewarded And now alot more of you are reading my pessimism rate of change tracker note , it is on my substack as well and I keep writing at end of quarter @valueequityin" target="_blank" rel="nofollow noopener">substack.com/@valueequityin disc: biased , no fresh reco, no direct investment advice !

@ishmohit1 OMG

Read this ⬇️⬇️

@Prakashplutus TACO effect !

🙏🙏🙏💚💚

@darshanvmehta1 Really there is any connection! 😜😜

Now liberals will say no connection to Modi speech and cease fire...lol